Trial Profile

Phase 1 SAD/MAD clinical study of subcutaneous injection formulation Oxyntomodulin analogue

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 23 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oxyntomodulin (Primary)
Indications Obesity
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

23 Feb 2026 New trial record
04 Feb 2026 According to an OPKO Health media release, OPKO is planning to initiate a single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1 clinical study with the subcutaneous injection formulation, initial data is expected by the end of 2026. Entera and OPKO plan to file an IND for the oral OXM tablet formulation thereafter.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com